Cardiovascular disease gets personal.
Hayden
Erika Check
EC
D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000235:genetics*; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005820:Genetic Testing; D014644:Genetic Variation; D055106:Genome-Wide Association Study; D023281:Genomics / Q000639:trends; D006801:Humans; D010597:Pharmacogenetics / Q000639:trends*; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000068799:Prasugrel Hydrochloride; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D000925:Anticoagulants; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D014859:Warfarin; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D013988:Ticlopidine
N Engl J Med. 2009 Jan 22;360(4):363-75
19106083
Diabetes. 2008 Nov;57(11):3129-35
18591388
Lancet. 2009 Jan 24;373(9660):309-17
19108880
N Engl J Med. 2008 Nov 20;359(21):2220-32
19020324
N Engl J Med. 2009 Jan 22;360(4):354-62
19106084
Nature. 2007 Jul 19;448(7151):353-7
17603472
Ann Intern Med. 2009 Jan 20;150(2):65-72
19153409
Diabetes. 2008 Nov;57(11):3122-8
18694974
Ann Intern Med. 2009 Jan 20;150(2):73-83
19153410
Nat Genet. 2009 Aug;41(8):876-8
19597491
Nat Genet. 2009 Aug;41(8):879-81
19597492
Circulation. 2007 Nov 27;116(22):2563-70
17989110